Does transforming growth factor-β1 predict for radiation-induced pneumonitis in patients treated for lung cancer?

Cytokine

Volumn 35, Issue 3-4, 2006, Pages 186-192

  Evans, Elizabeth S ^a   Kocak, Zafer ^a   Zhou, Su Min ^a   Kahn, Daniel A ^a   Huang, Hong ^a   Hollis, Donna R ^a   Light, Kim L ^a   Anscher, Mitchell S ^a   Marks, Lawrence B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Radiation pneumonitis; TGF 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; DOSIMETRY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PNEUMONIA; PRIORITY JOURNAL; RADIATION INJURY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION PNEUMONITIS; RADIOTHERAPY DOSAGE; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33750526481     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.07.021     Document Type: Article

References (40)

1. Anscher M.S., Marks L.B., Shafman T.D., Clough R., Huang H., Tisch A., et al. Risk of long-term complications after TGF-β1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 56 (2003) 988-995
2. Fan M., Marks L.B., Hollis D., Bentel G.G., Anscher M.S., Sibley G., et al. Can we predict radiation-induced changes in pulmonary function based on the sum of predicted regional dysfunction?. J Clin Oncol 19 (2001) 543-550
3. 30 and transforming growth factor β. Int J Radiat Oncol Biol Phys 50 (2001) 899-908
4. Graham M.V., Purdy J.A., Emami B., Harms W., Bosch W., Lockett M.A., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 (1999) 323-329
5. Marks L.B. The pulmonary effects of thoracic irradiation. Oncology (Huntingt) 8 (1994) 89-106
6. Marks L.B., Fan M., Clough R., Munley M., Bentel G., Coleman R.E., et al. Radiation-induced pulmonary injury: symptomatic versus subclinical endpoints. Int J Radiat Biol 76 (2000) 469-475
7. De Jaeger K., Seppenwoolde Y., Kampinga H.H., Boersma L.J., Belderbos J.S.A., and Lebesque J.V. Significance of plasma transforming growth factor-β levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1378-1387
8. Kwa S.L.S., Lebesque J.V., Theuws J.C.M., Marks L.B., Munley M.T., Bentel G., et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42 (1998) 1-9
9. Marks L.B. Dosimetric predictors of radiation-induced lung injury. Int J Radiat Oncol Biol Phys 54 (2002) 313-316
10. Seppenwoolde Y., Lebesque J.V., De Jaeger K., Belderbos J.S.A., Boersma L.J., Schilstra C., et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys 55 (2003) 724-735
11. Yorke E.D., Jackson A., Rosenzweig K.E., Merrick S.A., Gabrys D., Venkatraman E.S., et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54 (2002) 329-339
12. Anscher M.S., Murase T., Prescott D.M., Marks L.B., Reisenbichler H., Bentel G.C., et al. Changes in plasma TGFβ levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys 30 (1994) 671-676
13. Anscher M.S., Kong F.-M., Marks L.B., Bentel G.C., and Jirtle R.L. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 37 (1997) 253-258
14. Anscher M.S., Kong F.-M., Andrews K., Clough R., Marks L.B., Bentel G., et al. Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 41 (1998) 1029-1035
15. Novakova-Jiresova A., van Gameren M.M., Coppes R.P., Kampinga H.H., and Groen H.J.M. Transforming growth factor-β plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 71 (2004) 183-189
16. Hasegawa Y., Takanashi S., Kanehira Y., Tsushima T., Imai T., and Okumura K. Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91 (2001) 964-971
17. Teicher B.A. Malignant cells, directors of the malignant process: Role of transforming growth factor-beta. Cancer Metastasis Rev 20 (2001) 133-143
18. Vujaskovic Z., Marks L.B., and Anscher M.S. The physical parameters and molecular events associated with radiation-induced lung toxicity. Semin Radiat Oncol 10 (2000) 296-307
19. Asselin-Paturel C., Echchakir H., Carayol G., Gay F., Opolon P., Grunenwald D., et al. Quantitative analysis of Th1, Tb2 and TGF-β1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 77 (1998) 7-12
20. Blobe G.C., Schiemann W.P., and Lodish H.F. Mechanisms of disease: role of transforming growth factor (beta) in human disease. N Engl J Med 342 (2000) 1350-1358
21. Colasante A., Mascetra N., Brunetti M., Lattanzio G., Diodoro M., Galtagirone S., et al. Transforming growth factor beta 1, interleukin-8 and interleukin-1, in non-small-cell lung tumors. Am J Respir Crit Care Med 156 (1997) 968-973
22. Colasante A., Aiello F.B., Brunetti M., and di Giovine F.S. Gene expression of transforming growth factor β receptors I and II in non-small-cell lung tumors. Cytokine 24 (2003) 182-189
23. Kang Y., Prentice M.A., Mariano J.M., Davarya S., Linnoila R.I., Moody T.W., et al. Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis. Exp Lung Res 26 (2000) 685-707
24. Levinson B., Marks L.B., Munley M.T., Poulson J., Hollis D., Jaszczak R., et al. Regional dose response to pulmonary irradiation using a manual method. Radiother Oncol 48 (1998) 53-60
25. Marks L.B., Spencer D.P., Bentel G.C., Ray S.K., Sherouse G.W., Sontag M.R., et al. The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. Int J Radiat Oncol Biol Phys 26 (1993) 659-668
26. Marks L.B., Munley M.T., Bentel G.C., Zhou S.M., Hollis D., Scarfone C., et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 39 (1997) 563-570
27. Marks L.B., Sherouse G.W., Munley M.T., Bentel G.C., and Spencer D.P. Incorporation of functional status into dose-volume analysis. Med Phys 26 (1999) 196-199
28. Kang S.K., Rabbani Z.N., Folz R.J., Golson M.L., Huang H., Yu D., et al. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int J Radiat Oncol Biol Phys 57 (2003) 1056-1066
29. Border W.A., and Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 90 (1992) 1-7
30. Boyd F.T., and Massague J. Transforming growth factor-beta inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor. J Biol Chem 264 (1989) 2272-2278
31. Frater-Schroder M., Muller G., Birchmeier W., and Bohlen P. Transforming growth factor-beta inhibits endothelial cell proliferation. Biochem Biophys Res Commun 137 (1986) 295-302
32. Barcellos-Hoff M.H. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiat Res 150 (1998) S109-S120
33. Chen Y., Williams J., Ding I., Hernady E., Liu W., Smudzin T., et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 12 (2002) 26-33
34. Vujaskovic Z., and Groen H.J.M. TGF-β, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol 76 (2000) 511-516
35. Kong F.M., Anscher M.S., Murase T., Abbott B.D., Iglehart J.D., and Jirtle R.L. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 222 (1995) 155-162
36. Anscher M., Thrasher B., Rabbani Z., Teicher B., and Vujaskovic Z. Anti-TGF-β antibodies may prevent lung injury following high dose fractionated radiation. Int J Radiat Oncol Biol Phys 63 Suppl. 1 (2005) S83
37. Kong F.M., Anscher M.S., Sporn T.A., Washington M.K., Clough R., Barcellos-Hoff M.H., et al. Loss of heterozygosity at the mannos 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. Int J Radiat Oncol Biol Phys 49 (2001) 35-41
38. Hart J.P., Broadwater G., Rabbani Z., Moeller B.J., Clough R., Huang D., et al. Cytokine profiling for prediction of symptomatic radiation-induced lung injury. Int J Radiat Oncol Biol Phys 63 (2005) 1448-1454
39. Gridley D.S., Bonnet R.B., Bush D.A., Franke C., Cheek G.A., Slater J.D., et al. Time course of serum cytokines in patients receiving proton or combined photon/proton beam radiation for resectable but medically inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 60 (2004) 759-766
40. Barthelemy-Brichant N., Bosquee L., Cataldo D., Corhay J.L., Gustin M., Seidel L., et al. Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys 58 (2004) 758-767